Pfizer Macugen, C0X-2 Updates Expected At Nov. 30 Analyst Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The meeting is expected to focus on Pfizer's pipeline, including the inhaled insulin Exubera and insomnia agent indiplon. Pfizer will likely discuss safety profile of its COX-2 inhibitors.